D.A. Davidson & Co. Cellectis S.A. Transaction History
D.A. Davidson & Co.
- $12.1 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding CLLS
# of Institutions
34Shares Held
14.2MCall Options Held
3.1KPut Options Held
1.7K-
Long Focus Capital Management, LLC San Juan, PR4.62MShares$5.86 Million0.28% of portfolio
-
B Group, Inc. Dallas, TX3.08MShares$3.91 Million3.39% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$2.35 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.44MShares$1.83 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$1.83 Million0.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $57.8M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...